⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for syngeneic bone marrow transplantation

Every month we try and update this database with for syngeneic bone marrow transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaNCT00002522
Lymphoma
cisplatin
cyclophosphamid...
etoposide
autologous bone...
bone marrow abl...
peripheral bloo...
syngeneic bone ...
radiation thera...
15 Years - 70 YearsTemple University
Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesNCT00716066
Autoimmune Dise...
Neurologic Auto...
Autologous Tran...
Multiple Sclero...
MS Stem Cell Tr...
Multiple Sclero...
Stiff Person Sy...
HCT for Neurolo...
CIDP Transplant
Myasthenia Grav...
Autoimmune Nerv...
Central Nervous...
Cerebellar Dege...
Chronic Inflamm...
Lambert Eaton M...
Myasthenia Grav...
Neuromyelitis O...
Opsoclonus Myoc...
Rasmussen Subac...
Anti-Thymocyte ...
Autologous Hema...
Carmustine
Cytarabine
Etoposide
Laboratory Biom...
Melphalan
Peripheral Bloo...
Prednisone
Syngeneic Bone ...
- 71 YearsFred Hutchinson Cancer Center
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic SyndromeNCT00002547
Leukemia
Myelodysplastic...
busulfan
cyclophosphamid...
cyclosporine
cytarabine
methotrexate
allogeneic bone...
syngeneic bone ...
- 60 YearsBarbara Ann Karmanos Cancer Institute
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaNCT00002522
Lymphoma
cisplatin
cyclophosphamid...
etoposide
autologous bone...
bone marrow abl...
peripheral bloo...
syngeneic bone ...
radiation thera...
15 Years - 70 YearsTemple University
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple MyelomaNCT00002552
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
carmustine
cyclophosphamid...
cytarabine
etoposide
leucovorin calc...
methotrexate
perfosfamide
therapeutic hyd...
allogeneic bone...
autologous bone...
in vitro-treate...
peripheral bloo...
syngeneic bone ...
radiation thera...
- 70 YearsBarbara Ann Karmanos Cancer Institute
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: